Hangzhou Bio-Sincerity Pharma-Tech's (SHE:301096) controlling shareholders agreed to terminate the proposal to change the company's control, according to a Shenzhen bourse filing on Monday.
The decision was made with related parties due to the complexity of the matter.
The drug research and development company's shares slumped by less than 10% at the close.